Loading
A phase 1/2 trial of Pembrolizumab and Ivonescimab in advanced solid tumours, run by Shanghai JMT-Bio Inc., now recruiting.
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT06877650 by Shanghai JMT-Bio Inc., with 436 participants planned, started 2025-04-11 and due to reach its primary completion in 2028-03-30. Interventions recorded: JMT108, Pembrolizumab and Ivonescimab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/